The FDA on November 15, 2024, approved REVUFORJ®, a menin inhibitor, for Relapsed or Refractory Acute Leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. REVUFORJ® is a product of Syndax Pharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
